|Bid||0.37 x 1100|
|Ask||0.42 x 2000|
|Day's Range||0.39 - 0.42|
|52 Week Range||0.35 - 1.48|
|PE Ratio (TTM)||-1.30|
|Earnings Date||Jul 31, 2017 - Aug 4, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||0.70|
--Phase 1 clinical trial will evaluate the effect of ipilimumab and evofosfamide in advanced solid tumors--. --Company management to host“ Hypoxia and Immunotherapy” conference call today at 4:15 p.m. ...
TAIPEI, Taiwan, June 1, 2017 /PRNewswire/ -- OBI Pharma, Inc., a Taiwan biopharma company (TPex: 4174), announced today an agreement with Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) to acquire TH-3424, ...
NEW YORK, NY / ACCESSWIRE / May 23, 2017 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) stock ...